Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer

By afschroeder • June 12, 2025

Silverstein J, Smick A, Johnson B, Konecny GE. Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. Future Oncol. 2025 Jun 12:1-11. doi: 10.1080/14796694.2025.2513848. Epub ahead of print. PMID: 40501444.

Tags: antibody drug conjugates, Fellow, folate receptor, gynecologic cancer, Hematology/Oncology, Mirvetuximab, ovarian cancer, Publications

Understanding Barriers to Colon Cancer Screening Among Individuals Experiencing Housing Insecurity in Los Angeles

Burra A, Gonzales N, Jiang J, Zhang S, Obasi M, Eeraveni A, Garcia Jimenez M, Goldgar S. Understanding Barriers to Colon Cancer Screening Among Individuals[...]

Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy

Haidar AJ, Chen A, Chen JL, Al-Hashimi S, Ghaffari RS, Fung S, Silverstein J, Konecny GE, Tsui E. Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy.[...]

Expanding Lung Cancer Clinical Trial Criteria: A Systematic Review on Inclusion of Patients with Brain Metastases and Leptomeningeal Disease

Riano I, Velez MA, Pomares-Millan H, Blaquier J, Peshin S, Feldman J, Velazquez AI. Expanding Lung Cancer Clinical Trial Criteria: A Systematic Review on Inclusion[...]